237 related articles for article (PubMed ID: 35282039)
1. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
2. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
3. Systematic Profiling of Alternative Splicing Events in Ovarian Cancer.
Liu J; Lv D; Wang X; Wang R; Li X
Front Oncol; 2021; 11():622805. PubMed ID: 33763357
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer.
Sun T; Yang Q
Oncol Lett; 2020 Jul; 20(1):420-430. PubMed ID: 32565967
[TBL] [Abstract][Full Text] [Related]
6. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
8. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
Zhu J; Chen Z; Yong L
Gynecol Oncol; 2018 Feb; 148(2):368-374. PubMed ID: 29191436
[TBL] [Abstract][Full Text] [Related]
9. Assessing of programmed cell death gene signature for predicting ovarian cancer prognosis and treatment response.
Lian X; Liu B; Wang C; Wang S; Zhuang Y; Li X
Front Endocrinol (Lausanne); 2023; 14():1182776. PubMed ID: 37342266
[TBL] [Abstract][Full Text] [Related]
10. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
[TBL] [Abstract][Full Text] [Related]
11. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
12. A comprehensive characterization of alternative splicing events related to prognosis and the tumor microenvironment in lung adenocarcinoma.
Ma S; Zhu J; Wang M; Han T; Zhu J; Jiang R; Jiang T
Ann Transl Med; 2022 Apr; 10(8):479. PubMed ID: 35571443
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma.
Cao R; Zhang J; Jiang L; Wang Y; Ren X; Cheng B; Xia J
Front Oncol; 2020; 10():1740. PubMed ID: 32984057
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Characterization of Alternative mRNA Splicing Events in Glioblastoma: Implications for Prognosis, Molecular Subtypes, and Immune Microenvironment Remodeling.
Zhao L; Zhang J; Liu Z; Wang Y; Xuan S; Zhao P
Front Oncol; 2020; 10():555632. PubMed ID: 33575206
[TBL] [Abstract][Full Text] [Related]
15. Alternative Splicing: A New Therapeutic Target for Ovarian Cancer.
Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
[No Abstract] [Full Text] [Related]
16. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
17. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
18. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
Front Oncol; 2021; 11():778637. PubMed ID: 35004299
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer.
Wang S; Wang S; Zhang X; Meng D; Xia Q; Xie S; Shen S; Yu B; Hu J; Liu H; Yan W
RNA Biol; 2022 Jan; 19(1):1007-1018. PubMed ID: 35980273
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
Liu J; Liu Y; Yang C; Liu J; Hao J
Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
